Repare Therapeutics Inc (Nasdaq: RPTX), a clinical-stage precision oncology firm, announced on Wednesday that it has reported updated safety and tolerability results from its Phase 1 MYTHIC clinical trial. The trial evaluates the combination of lunresertib, a first-in-class PKMYT1 inhibitor, and camonsertib, an oral ATR inhibitor (lunre+camo), in patients with various tumour types.

Presented at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain, the data show that an individualised treatment schedule effectively mitigates mechanism-based anaemia while maintaining clinical efficacy. The analysis tracked patients for approximately nine months at the recommended Phase 2 dose (RP2D), confirming no instances of thrombocytopenia or serious neutropenia.

Key findings include a reduction in Grade 3 anemia from 51.4% to 22.6%, attributed to optimized dosing schedules. Anemia was more frequent among patients with baseline hemoglobin below 11 g/dL, with the new regimen significantly lowering the incidence of red blood cell transfusions and dose interruptions. Clinical benefit, as measured by radiographic regressions and molecular responses, remained consistent, with no observed negative impact on progression-free survival after changing treatment schedules.

Repare Therapeutics employs a proprietary synthetic lethality approach to develop targeted cancer therapies. Its pipeline includes lunresertib and camonsertib, both currently in Phase 1/2 clinical development, as well as other preclinical programs targeting genomic instability and DNA damage repair.